Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RU-41740
- Development stage
- Unknown
- Administration
- Oral
01
Overview
RU-41740 is an **immunomodulating agent** of organic origin extracted from *Klebsiella pneumoniae*. It is primarily composed of carbohydrates with a minor protein portion. The active principle consists of two repetitive glycoprotein subunits: **P1 (95 kD)** from the bacterial capsule and **F1 (350 kD)** from the external bacterial membrane[4]. RU-41740 acts by enhancing host immune defenses, particularly by boosting phagocytosis and candidacidal activity of monocytes, and modulating polymorphonuclear neutrophil functions[3][5]. It is used **preventively against recurrent respiratory infections** in both adults and children and has demonstrated immunological safety in preclinical and clinical studies[1][3]. Orally administered RU-41740 crosses the intestinal wall and rapidly enters the lymphatic system[4].
- Brand names
- RU-41740RU41740RU 41740
- Other names
- RU-41740RU41740RU 41740
Beyond the preview
Go deeper on RU-41740.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RU-41740.